Literature DB >> 7936666

Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.

A Brunet1, G Pagès, J Pouysségur.   

Abstract

The Mitogen Activated Protein Kinase (MAPK) module operates downstream of Ras to convey cell surface signals to the nucleus via the nuclear translocation of p42/p44 MAPKs. We have previously established that MAPK activation is obligatory and must persist in the G1 phase to allow resting fibroblasts to exit from G0 (Pagès et al., Proc. Natl. Acad. Sci.1993, 90, 8319-8323). It remained to be established whether MAPK activation was sufficient to trigger cell proliferation. To this aim, we generated and expressed in Chinese hamster lung fibroblasts, constitutively active mutants of hamster MAP kinase kinase (MAPKK). Three mutants: S218D, S222D and S218D/S222D in which we substituted the Raf1/MAPKKK-dependent regulatory phosphorylation sites by aspartic acid residues, displayed increased basal activity when expressed in fibroblasts. Two of them, S218D and S218D/S222D which have a basal activity higher than serum-stimulated wild type-MAPKK (respectively 2- and 5-fold), induced activation of p42 MAPK in growth factor-deprived cells. Interestingly, only these two mutants led to a growth factor-independent state as judged by early gene transcription (activation of the fos promoter), increased sensitivity to growth factors for reinitiation of DNA synthesis, autonomous cell cycling and rapid tumor formation in nude mice. Therefore we conclude that the downstream elements of the growth factor signalling cascade, MAPKK-MAPK, are both necessary and sufficient to promote growth factor signals and autonomous cell cycling in fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936666

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  60 in total

1.  The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal.

Authors:  M Le Gall; J C Chambard; J P Breittmayer; D Grall; J Pouysségur; E Van Obberghen-Schilling
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

2.  Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Authors:  M C Rouyez; C Boucheron; S Gisselbrecht; I Dusanter-Fourt; F Porteu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Activation of tomato PR and wound-related genes by a mutagenized tomato MAP kinase kinase through divergent pathways.

Authors:  T Xing; K Malik; T Martin; B L Miki
Journal:  Plant Mol Biol       Date:  2001-05       Impact factor: 4.076

4.  The tumor suppressor p53 inhibits Net, an effector of Ras/extracellular signal-regulated kinase signaling.

Authors:  Koji Nakade; Hong Zheng; Gitali Ganguli; Gilles Buchwalter; Christian Gross; Bohdan Wasylyk
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

5.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

6.  The mammalian mitogen activated protein kinase network.

Authors:  P Lenormand
Journal:  Clin Mol Pathol       Date:  1995-12

7.  Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.

Authors:  Jihane Basbous; Dany Chalbos; Robert Hipskind; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2007-03-19       Impact factor: 4.272

8.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

9.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

10.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

Authors:  G Bunone; P A Briand; R J Miksicek; D Picard
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.